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Effects of intravenous administration of polymyxin B in neonatal foals with
experimental endotoxemia
Abstract
Objective—To evaluate the effect of IV administration of polymyxin B on clinical and serum biochemical
variables in foals with experimental endotoxemia.
Design—Prospective experimental study.
Animals—14 healthy neonatal foals.
Procedures—Foals were randomly assigned to a treatment or control group and were administered a single
dose of lipopolysaccharide (0.5 μg/kg [0.23 μg/lb]) IV over 30 minutes. The treatment group received
polymyxin B (6,000 U/kg [2,727 U/lb], IV) immediately after completion of lipopolysaccharide infusion; the
control group was administered an equal volume of saline (0.9% NaCl) solution. Subsequent doses of
polymyxin B or saline solution were administered IV at 8 and 16 hours. Blood was collected at various time
points, and outcome variables, including heart rate, respiratory rate, rectal temperature, attitude score, WBC
count, neutrophil count, lymphocyte count, monocyte count, platelet count, Hct, blood lactate concentration,
blood glucose concentration, serum tumor necrosis factor-α concentration, and plasma thromboxane B2
concentration, were measured. Urine was collected prior to and after experimentation to determine whether
nephrotoxicosis was associated with treatment.
Results—The treatment group had significantly lower blood lactate concentration and serum tumor necrosis
factor-α and plasma thromboxane B2 concentrations and had higher blood glucose concentrations and better
attitude scores, compared with the control group, at various time points during the study. No other significant
differences and no evidence of overt nephrotoxicosis were detected.
Conclusions and Clinical Relevance—Administration of polymyxin B IV in healthy neonatal foals
challenged with lipopolysaccharide attenuated some clinical and serum biochemical derangements associated
with endotoxemia.
Disciplines
Comparative and Laboratory Animal Medicine | Large or Food Animal and Equine Medicine | Veterinary
Physiology | Veterinary Preventive Medicine, Epidemiology, and Public Health | Veterinary Toxicology and
Pharmacology
Comments
This article is from Journal of the American Veterinary Medical Association 243 (2013): 874, doi: 10.2460/
javma.243.6.874. Posted with permission.
Authors
David M. Wong, Brett A. Sponseller, Cody J. Alcott, Prince N. Agbedanu, Chong Wang, and Walter H. Hsu
This article is available at Iowa State University Digital Repository: http://lib.dr.iastate.edu/vdpam_pubs/80
874 Scientific Reports  JAVMA, Vol 243, No. 6, September 15, 2013
E
Q
U
IN
E
Septicemia is a common clinical entity in neonatal foals, and this disease process and its associated 
complications (eg, septic arthritis) are one of the lead-
ing causes of morbidity and death in neonatal foals.1,2 
Although various bacterial organisms have been rec-
ognized in equine neonatal septicemia, gram-negative 
bacteria account for 70% to 95% of the microorgan-
isms isolated from bacteriologic cultures of blood, with 
Escherichia coli being most commonly identified.2–4 
Incorporated in the outer membrane of gram-negative 
bacteria is LPS (endotoxin), which plays a pivotal role 
in host response to bacterial invasion by promoting 
inflammation via production of prostaglandins, sero-
tonin, kinins, inflammatory interleukins, and other me-
diators.5,6 Clinically, endotoxemia has been reported in 
10% to 50% of neonatal foals (≤ 14 days of age) evalu-
ated at equine referral hospitals for treatment of pre-
sumed septicemia.7,8 Possible sequelae of gram-negative 
septicemia and associated endotoxemia include exag-
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Objective—To evaluate the effect of IV administration of polymyxin B on clinical and serum 
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ministered a single dose of lipopolysaccharide (0.5 µg/kg [0.23 µg/lb]) IV over 30 minutes. 
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volume of saline (0.9% NaCl) solution. Subsequent doses of polymyxin B or saline solution 
were administered IV at 8 and 16 hours. Blood was collected at various time points, and 
outcome variables, including heart rate, respiratory rate, rectal temperature, attitude score, 
WBC count, neutrophil count, lymphocyte count, monocyte count, platelet count, Hct, 
blood lactate concentration, blood glucose concentration, serum tumor necrosis factor-α 
concentration, and plasma thromboxane B2 concentration, were measured. Urine was col-
lected prior to and after experimentation to determine whether nephrotoxicosis was associ-
ated with treatment.
Results—The treatment group had significantly lower blood lactate concentration and se-
rum tumor necrosis factor-α and plasma thromboxane B2 concentrations and had higher 
blood glucose concentrations and better attitude scores, compared with the control group, 
at various time points during the study. No other significant differences and no evidence of 
overt nephrotoxicosis were detected.
Conclusions and Clinical Relevance—Administration of polymyxin B IV in healthy neona-
tal foals challenged with lipopolysaccharide attenuated some clinical and serum biochemical 
derangements associated with endotoxemia. (J Am Vet Med Assoc 2013;243:874–881)
gerated activation of the inflammatory response, activa-
tion of the coagulation cascade, and derangements in 
multiple organ systems (eg, cardiovascular, respiratory, 
or hemostatic).7,9 Subsequently, derangements in organ 
function and biochemical alterations may progress to 
shock, multiorgan failure, and death.7,9
Scientific investigation has elucidated the mecha-
nisms of cellular initiation and activation of inflam-
mation induced by LPS, which has provided targets 
for therapeutic intervention.10,11 As such, drugs that 
interfere with the molecular sequence of events of cel-
lular activation of inflammation may lessen the exag-
gerated activation of inflammation and improve clini-
cal severity and outcome in patients with septicemia 
or endotoxemia.10–12 Polymyxin B sulfate is a readily 
available and affordable cationic antimicrobial with a 
broad range of activity against gram-negative bacteria. 
In addition to having antimicrobial properties, poly-
myxin B functions as a chelating agent by binding the 
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lipid A portion of LPS in a 1:1 ratio, thus neutralizing 
LPS and negating the interaction of LPS with cellular 
receptors that results in inflammation.13–15 Positive ef-
fects of IV administration of polymyxin B have been 
determined in experimental endotoxemia studies15–19 
in adult horses, with significant decreases in concen-
trations of inflammatory mediators (TNF-α and TXB2) 
as well as improved clinical attitude (eg, activity level, 
appetite, and mentation) scores in horses treated with 
polymyxin B, compared with control horses. Treatment 
with polymyxin B to attenuate clinical endotoxemia is 
frequently used in adult horses for conditions such as 
strangulating intestinal lesions, pleuropneumonia, and 
postpartum metritis, with purported beneficial effects.20 
In light of the high prevalence of gram-negative septi-
cemia and endotoxemia in neonatal foals, a search for 
a safe, affordable, and effective treatment is warranted 
to improve the clinical course and outcome of equine 
neonatal septicemia. To our knowledge, no studies have 
been reported regarding the IV use of polymyxin B for 
equine neonatal septicemia or endotoxemia; therefore, 
the objective of the study reported here was to deter-
mine whether beneficial clinical and serum biochemi-
cal effects are observed in neonatal foals with experi-
mental endotoxemia administered polymyxin B IV.
Materials and Methods
Animals—Fourteen healthy neonatal foals (Thor-
oughbreds and Quarter Horses) with a mean age of 
3.9 days (range, 3 to 5 days) and mean body weight of 
60.5 kg (133.1 lb; range, 46 to 65 kg [101.2 to 143 lb]) 
were used for this study after approval by the Institu-
tional Animal Care and Use Committee of Iowa State 
University. The 8 fillies and 6 colts were assigned to 1 
of 2 groups via block randomization and drawing of a 
piece of paper identifying the foal as receiving either 
polymyxin B or saline (0.9% NaCl) solution (control). 
Experimentation was performed on each foal individu-
ally, with no overlap among foals; foals remained with 
their dams during the study period. 
Initial evaluation and instrumentation—Twenty-
four hours prior to administration of LPS, all foals were 
determined to be healthy on the basis of a complete 
physical examination, evaluation of adequate transfer 
of maternal antibodies (at ≥ 24 hours of age) with a 
commercial ELISA,a and CBC results. Subsequently, the 
foals were sedated with xylazineb (1 mg/kg [0.45 mg/
lb], IV) and an 18-gauge, 3-inch IV catheterc was placed 
by means of an aseptic technique in each jugular vein 
(2 catheters/foal). In addition, urine was collected via 
urinary bladder catheterization with a sterile catheter.d 
Heparinized saline solution (3 mL) was flushed through 
each IV catheter every 6 hours to maintain patency.
Administration of LPS and polymyxin B—The 
following day, all foals were administered LPS (O55:B5 
E coli)e diluted in 50 mL of saline solution (dose, 0.5 
µg/kg [0.23 µg/lb]), via the IV route (left jugular cath-
eter), as described,21–23 over a 30-minute period with an 
electronic syringe pump (start of LPS infusion = time 
0). Seven foals were randomly assigned to the treatment 
group and were administered 6,000 U of polymyxin Bf/
kg (2,727.3 U/lb) diluted in 12 mL of saline solution, IV, 
as a bolus immediately after the end of the LPS infusion 
(0.5 hours). Similarly, 7 foals were randomly assigned 
to the control group and were administered an equal 
volume of saline solution IV at 0.5 hours. Subsequent 
doses of polymyxin B (6,000 U/kg; treatment group) or 
saline solution (control group) were administered IV at 
8 and 16 hours.
Sample collection and clinical evaluation—Twelve 
milliliters of blood was collected from the right jugular 
catheter at –24, –0.5, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 
24, and 48 hours and placed in EDTA and serum clot 
tubes. Serum was harvested from samples not used for 
CBC, blood lactate analysis, or blood glucose analysis 
and stored at –80oC until samples from all foals had 
been collected. Physical examination variables includ-
ing heart rate, respiratory rate, and rectal temperature 
were recorded at the same time as blood collection. 
Each time blood was obtained, a subjective attitude 
score was determined by an observer unaware of group 
assignments on the basis of the following criteria: 1 = 
bright and alert; 2 = signs of depression (head hanging 
and lethargic), but suckling; 3 = signs of depression and 
not suckling; and 4 = comatose (recumbent and unable 
to rise).21–23 Urine was obtained at 24 hours either via 
free catch (9 foals) or urinary bladder catheterization (4 
foals) by use of light sedation (xylazine [1 mg/kg, IV]).
Assays—A CBC including a WBC count, neu-
trophil count, lymphocyte count, monocyte count, 
platelet count, and Hct was performed immediately 
after blood collection with an automated hematology 
machine.g Blood lactate concentrationh and blood glu-
cosei concentration were also measured immediately 
after blood collection with point-of-care monitors val-
idated for horses.24,25 Urine creatinine concentration 
and GGT activity were measured (–24 and 24 hours) 
by use of an automated chemistry analyzerj with com-
mercially available reagents and standards. Urine GGT 
(U/L)-to-creatinine (mmol/L) ratio was calculated.26 
After samples were collected from all 14 foals, serum 
was thawed and purified by removing interfering sub-
stances with C-18 solid-phase extraction columns.k 
Tumor necrosis factor-α and TXB2 were measured via 
commercially available assaysl,m following the manu-
facturer’s instructions.
Statistical analysis—Data for response variables 
(heart rate, respiratory rate, rectal temperature, atti-
tude score, WBC count, neutrophil count, lymphocyte 
count, monocyte count, platelet count, Hct, blood lac-
tate concentration, blood glucose concentration, serum 
TNF-α concentration, and plasma TXB
2
 concentration) 
from the treatment and control groups were reported 
as mean ± SD values. Effects of treatment and time on 
response variables were analyzed via repeated-measures 
ANOVA. Tumor necrosis factor-α and TXB
2
 concentra-
tion measurements were log transformed to facilitate 
analysis via ANOVA. Treatment, time, and their interac-
tion were used as fixed effect, whereas the foal was the 
subject of repeated measures. Baseline outcome values 
were used as covariates in analyses. Significance was set 
at P ≤ 0.05.
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Results
Physical examination variables and attitude 
score—All foals developed mild to moderate signs of 
colic as well as diarrhea within 1 hour after LPS ad-
ministration. Mucous membranes became extremely 
congested, and scleral vasculature was prominent. Ad-
ditionally, marked lethargy, lack of awareness of their 
environment, and lack of suckling between 1 and 2 
hours (range, 0.5 to 5 hours) were observed in all 
foals. In the control group, a significant increase in 
heart rate (at 8 hours) and decrease in respiratory rate 
(at 2 hours) were observed, compared with time 0. In 
the polymyxin B group, a significant increase in rectal 
temperature was observed at 4, 5, and 6 hours, com-
pared with time 0. No difference in rectal tempera-
ture, heart rate, or respiratory rate was observed at any 
time point when the control group was 
compared with the polymyxin B group 
(Table 1). 
The attitude score was significantly 
increased in both groups at various time 
points, compared with time 0 (Table 1). 
A significantly lower (ie, improved) at-
titude score was observed in the poly-
myxin B group, compared with the con-
trol group, at 4, 8, and 12 hours; attitude 
score was not significantly (P = 0.06) 
lower in the polymyxin B group at 1.5, 
5, and 6 hours, compared with the con-
trol group.
Blood glucose concentration—A 
significant decrease in blood glucose 
concentration was detected in the con-
trol and polymyxin B groups at vari-
ous time points, compared with time 
0 (Figure 1). The mean blood glucose 
concentration reached a nadir between 
3 and 4 hours after initiation of LPS in-
fusion. Blood glucose concentrations 
were significantly higher in the polymyxin B group at 
1.5, 4, and 5 hours, compared with the control group. 
Five hundred milliliters of 5% dextrose in water was 
administered at 4 hours to 1 foal in the polymyxin B 
group and 5 foals in the control group because the 
blood glucose concentration decreased to < 35 mg/dL; 
this treatment was instituted because the investiga-
tors were concerned that the blood glucose concentra-
tion would decrease to a life-threatening concentra-
tion without intervention. Of note, foals administered 
5% dextrose were included in the statistical analysis, 
although administration of dextrose likely affected 
blood glucose concentrations at subsequent times (≥ 
5 hours).
Blood lactate concentration—A significant in-
crease in blood lactate concentration was detected in 
        Time (h)       
Variable –24 –1 0 0.5 1 1.5 2 3 4 5 6 8 12 24 48
Temperature (°C [reference 
  range, 37.22°–38.89°C])               
    Control 38.67 ± 0.7 38.61 ± 0.5 38.61 ± 0.9 38.667 ± 0.7 38.67 ± 1 38.61 ± 1 38.39 ± 2 39.00 ± 2.3 39.22 ± 1 39.22 ± 1 39.17 ± 1 38.5 ± 0.5 38.72 ± 0.9 38.39 ± 0.7 38.5 ± 0.9
    Polymyxin B  38.5 ± 0.7 38.61 ± 0.9 38.67 ± 0.9 38.72 ± 1 38.89 ± 0.9 38.89 ± 2 38.72 ± 2 39.33 ± 1 39.56 ± 1 39.56 ± 1 39.39 ± 1 38.5 ± 0.9 38.5 ± 2 38.28 ± 2 38.61 ± 1
Heart rate (beats/min [reference 
  range, 70–100 beats/min])               
    Control 103 ± 9 107 ± 8 110 ± 10 84 ± 14 100 ± 21 121 ± 47 102 ± 25 99 ± 15 101 ± 17 125 ± 20 137 ± 28 150 ± 14* 134 ± 34 125 ± 20 111 ± 14
    Polymyxin B  95 ± 10 103 ± 23 101 ± 13 85 ± 12 115 ± 14 126 ± 28 98 ± 9 93 ± 14 104 ± 22 115 ± 25 128 ± 9 131 ± 15 125 ± 13 103 ± 5 96 ± 12
Platelet count (X 103 platelets/µL 
  [reference range, 
  105–353 X 103 platelets/µL])               
    Control 130 ± 42 103 ± 38 103 ± 40 84 ± 32 68 ± 28* 71 ± 32* 72 ± 27* 72 ± 28* 67 ± 23* 60 ± 20* 52 ± 21* 49 ± 19* 36 ± 15* 38 ± 17* 65 ± 15*
    Polymyxin B  191 ± 37 152 ± 44 152 ± 39 120 ± 40* 114 ± 44* 119 ± 33* 98 ± 33* 102 ± 31* 100 ± 35* 93 ± 32* 90 ± 39* 86 ± 37* 75 ± 36* 62 ± 28* 91 ± 32*
Hct (% [reference range, 
  30%–44%])               
    Control 33 ± 3 32 ± 4 32 ± 3 36 ± 4* 38 ± 4* 37 ± 3* 37 ± 4* 37 ± 5* 37 ± 4* 37 ± 5* 36 ± 4* 36 ± 4* 36 ± 4* 32 ± 4 30 ± 4
    Polymyxin B  34 ± 5 34 ± 5 33 ± 5 38 ± 6* 39 ± 4* 39 ± 4* 37 ± 4* 38 ± 4* 37 ± 5* 37 ± 4* 36 ± 4* 36 ± 4* 37 ± 4* 32 ± 4 30 ± 4
Attitude score               
    Control 1 1 1 3.1 ± 0.7* 3.4 ± 0.5* 3.9 ± 0.4* 3.3 ± 0.5* 2.9 ± 0.7* 3.3 ± 1* 2.4 ± 0.8* 2.1 ± 0.4* 2 ± 0.6* 1.9 ± 0.4 1.4 ± 0.5 1
    Polymyxin B 1 1 1 2.9 ± 1.2* 3.4 ± 0.5* 3.3 ± 0.5* 3.1 ± 0.4* 2.6 ± 0.5* 2.3 ± 1*† 1.9 ± 0.7 1.6 ± 0.5 1.1 ± 0.4† 1† 1 1
Reference ranges for healthy foals.27
*Significantly (P < 0.05) different from time 0 within a group. †Significantly (P < 0.05) different between groups.
Table 1—Mean ± SD values for variables measured at various times in foals given LPS (0.5 µg/kg [0.23 µg/lb], IV) over 30 minutes (start 
of infusion = time 0) and then given saline (0.9% NaCl) solution, IV, every 8 hours (control), or polymyxin B (6,000 U/kg [2,727.27 U/lb], IV, 
q 8 h) beginning 30 minutes after the start of LPS infusion.
Figure 1—Mean ± SD blood glucose concentrations of foals administered LPS (0.5 µg/
kg [0.23 µg/lb], IV, over 30 minutes; start of infusion = time 0) and then given saline 
(0.9% NaCl) solution, IV, every 8 hours (control; black squares) or polymyxin B (6,000 U/kg 
[2,727.27 U/lb], IV, q 8 h; white squares) beginning 30 minutes after the start of LPS infu-
sion. aSignificant (P < 0.05) difference between groups. *Significant (P < 0.05) difference 
from baseline (time 0) value within a group. Shaded area denotes reference interval in 
healthy foals.27  At 4 hours, 1 foal in the polymyxin B group and 5 foals in the control group 
were administered 500 mL of 5% dextrose, IV, as a bolus to treat severe hypoglycemia. 
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both groups at various time points, com-
pared with time 0 (Figure 2). The blood 
lactate concentration was significantly 
lower at 4 and 5 hours in the polymyx-
in B group, compared with the control 
group (Table 1).
Hematologic evaluation—A signifi-
cant change in the WBC and neutrophil 
counts was detected in both groups at 
various time points, compared with time 
0 (Figures 3 and 4). The WBC and neu-
trophil counts were significantly higher 
in the polymyxin B group at 8 hours, 
compared with the control group. In 
comparison, the WBC (48 hours) and 
neutrophil (24 and 48 hours) counts 
were significantly lower in the polymyx-
in B group, compared with the control 
group. A significant decrease in platelet 
count and increase in Hct were observed 
in both groups at various time points 
(Table 1). No significant difference in 
platelet count or Hct was detected be-
tween groups. No significant differences 
in lymphocyte or monocyte counts were 
detected within or between groups.
Serum TNF-α concentration—A 
significant increase in serum TNF-α 
concentration was detected between 
baseline (time 0) and 0.5 to 24 hours 
after LPS infusion in the control group 
and between baseline (time 0) and 0.5 to 
6 hours (P < 0.001) in the polymyxin B 
group (Figure 5). Peak TNF-α concen-
tration was detected at 1.5 hours in both 
groups. Foals in the polymyxin B group 
had significantly lower TNF-α concen-
trations at 8 and 24 hours, but not (P 
= 0.06) at 12 hours, compared with the 
control group.
Serum TXB
2
 concentration—A sig-
nificant increase in plasma TXB
2
 con-
centration was detected between base-
line (time 0) and 0.5 to 8 hours in both 
groups (Figure 6). Peak TXB
2
 concen-
tration was observed at the completion 
of the LPS infusion (0.5 hours) in both 
groups. Foals in the polymyxin B group 
had significantly lower TXB
2
 concen-
trations at 1, 2, and 3 hours, compared 
with the control group.
Urine GGT-to-creatinine ratio—
Urine was not obtained from 1 foal in 
the treatment group because the foal 
returned to its normal housing envi-
ronment prior to collection. The mean 
GGT-to-creatinine ratio before or after LPS administra-
tion for the polymyxin B group was 0.015 ± 0.018 or 
0.007 ± 0.003, respectively, whereas the mean GGT-to-
creatinine ratio before or after LPS administration for 
the control group was 0.008 ± 0.005 or 0.008 ± 0.003, 
respectively. No significant difference was found in the 
GGT-to-creatinine ratio before or after LPS administra-
tion within or between groups.
Figure 2—Mean ± SD blood lactate concentrations of the same foals as in Figure 1. 
See Figure 1 for remainder of key. 
Figure 3—Mean ± SD total WBC counts of the same foals as in Figure 1. See Figure 
1 for remainder of key. 
Figure 4—Mean ± SD neutrophil counts of the same foals as in Figure 1. See Figure 
1 for remainder of key. 
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Discussion
Septicemia and endotoxemia remain common clin-
ical entities in humans and veterinary species, driving 
investigations into treatments that improve patient wel-
fare, recovery, and outcome but have minimal adverse 
effects. Administration of antimicrobials is the corner-
stone of treatment for septicemia, but medications that 
attenuate the exaggerated inflammatory response asso-
ciated with septicemia can decrease patient morbidity 
and mortality rates.12 In the present study, IV adminis-
tration of polymyxin B resulted in improvement in at-
titude score as well as some clinicopathologic variables 
and concentrations of inflammatory mediators without 
evidence of overt nephrotoxicosis. This information 
suggested that polymyxin B may be a beneficial ancil-
lary treatment for equine neonatal endotoxemia and 
septicemia.
The observations of lethargy, failure to suckle, col-
ic, diarrhea, alterations in vascular perfusion, tachycar-
dia, and fever were consistent with other experimental 
studies21–23,28,29 of endotoxemia in foals 
as well as naturally occurring cases of 
equine neonatal septicemia. The attitude 
score was a subjective assessment as-
signed by an observer unaware of group 
assignments; this score was significantly 
better in the polymyxin B group at 4, 8, 
and 12 hours and approached signifi-
cance (P = 0.06) at 1.5, 5, and 6 hours in 
this study, suggesting some clinical ben-
efit. In addition, at various time points 
during this study, significant improve-
ment in blood glucose concentration 
and blood lactate concentration was de-
tected in foals that received polymyxin 
B, compared with control foals. Neona-
tal foals are susceptible to hypoglycemia 
because of low fat and glycogen reserves; 
thus, a neonatal foal that is not suckling 
can develop hypoglycemia rapidly.30 
Hypoglycemia is a common feature in ill 
neonatal foals evaluated at referral hos-
pitals, with 1 large retrospective study31 
detecting hypoglycemia at admission in 
34% of 515 neonatal foals. Furthermore, 
foals with blood glucose concentrations 
< 50 mg/dL at admission in that study31 
were associated with septicemia and 
positive results of bacteriologic culture 
of blood and were less likely to survive. 
In the present study, the mean blood 
glucose concentration reached its nadir 
3 to 4 hours after initiation of the LPS 
infusion, and hypoglycemia likely devel-
oped as a result of decreased to absent 
suckling behavior from 0.5 to 4 hours 
after LPS administration. As reflected in 
the attitude score, the foals in the poly-
myxin B group started to suckle sooner 
after LPS administration, compared with 
the control foals, thus increasing their 
blood glucose concentrations earlier 
and to a greater extent. In this study, 500 mL of 5% 
dextrose in water was administered IV to 1 foal in the 
polymyxin B group and 5 foals in the control group be-
cause of extremely low blood glucose concentrations 
(< 35 mg/dL) measured at 4 hours. This intervention 
may have compromised the ability to detect significant 
differences in blood glucose concentrations between the 
polymyxin B–treated and control foals at subsequent 
times (5 hours and after); however, concerns regarding 
severe hypoglycemia warranted intervention. Interest-
ingly, the blood glucose concentration at 5 hours was 
not markedly increased after dextrose administration, 
as would be suspected in a healthy foal, suggesting that 
an increased catabolic state secondary to endotoxemia 
and the systemic inflammatory response syndrome 
could have also been a factor in the development of 
hypoglycemia. Other potential causes of hypoglycemia 
include altered metabolism or function of endocrine 
glucoregulatory mechanisms (eg, insulin, glucagon, 
cortisol, and epinephrine), which has been observed in 
critically ill foals.32,33
Figure 5—Mean ± SD log of serum TNF-α concentrations in the same foals as in 
Figure 1. Serum TNF-α concentration was 0 pg/mL in 31 clinically normal foals.28 See 
Figure 1 for remainder of key. 
Figure 6—Mean ± SD log of plasma TXB2 concentrations of the same foals as in Fig-
ure 1. No published information is available for plasma TXB
2
 concentrations in healthy 
4-day-old foals. See Figure 1 for remainder of key. 
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Administration of LPS resulted in a significant in-
crease in blood lactate concentration, compared with 
baseline values, in both groups within 0.5 hour after 
completion of the LPS infusion. Hyperlactatemia has been 
used as a prognostic guide in ill neonatal foals, with blood 
lactate concentration significantly higher in nonsurviv-
ing foals.34–36 Hyperlactatemia can occur via a multitude 
of pathophysiologic mechanisms, with the most com-
mon mechanism arising from anaerobic tissue metabo-
lism, which occurs with an imbalance between oxygen 
delivery and tissue demand (type A hyperlactatemia).37 
Hyperlactatemia may also occur under conditions of ad-
equate oxygen delivery (type B hyperlactatemia) in the 
face of increased or impaired oxygen utilization secondary 
to the systemic inflammatory response syndrome, sepsis, 
neoplasia, or mitochondrial dysfunction.38 Type B hyper-
lactatemia can also occur from reduced lactate clearance 
in conditions such as liver or renal failure.38 Critically 
ill foals likely have both type A and type B hyperlactate-
mia.37,38 In the study reported here, the mean blood lactate 
concentration was significantly lower at 4 and 5 hours in 
the polymyxin B group, compared with the control group. 
Although the exact metabolic alterations causing hyper-
lactatemia were not examined in this study, this informa-
tion suggested that treatment of neonatal endotoxemia 
with polymyxin B potentially improves systemic oxygen-
ation or abates factors associated with the development of 
hyperlactatemia.
Similar to previous studies15,16,18,21 in adult horses 
and foals, LPS administration in this study resulted in 
marked leukopenia and neutropenia. In similar LPS 
studies15,18 investigating polymyxin B in adult horses, 
significantly higher neutrophil counts in the polymyxin 
B–treated horses, compared with control horses, were 
detected 1 hour after LPS infusion only when polymyx-
in B was administered prior to LPS infusion. Although 
a significant increase in neutrophil counts in the study 
reported here was detected in the polymyxin B group at 
8 hours, compared with the control foals, significantly 
lower neutrophil counts were reported at 24 and 48 
hours. Considering the time (8, 24, and 48 hours) at 
which these differences were detected, it is likely that 
the differences in neutrophil counts were associated 
with varying degrees of rebound neutrophilia com-
monly observed after a severe neutropenic episode.15,39 
Thus, it is unlikely that polymyxin B administration 
had any clinically beneficial effect on the WBC or neu-
trophil count in this study.
Significantly lower concentrations of 2 inflamma-
tory mediators, TNF-α and TXB
2
, were measured in the 
polymyxin B group, compared with the control group 
in this study. Tumor necrosis factor-α is a cytokine pro-
duced by activated macrophages and is an important 
proximal inflammatory mediator in the pathogenesis 
of endotoxemia.28 Increased serum concentrations of 
TNF-α have been detected after experimental adminis-
tration of endotoxin to foals as well as in clinical cases 
of equine neonatal septicemia; with the latter situation, 
higher TNF-α activity has been associated with a poor 
prognosis.29,40 In adult horses, significantly lower serum 
TNF-α activity was observed in horses that received 
polymyxin B (5,000 U/kg [2,272.73 U/lb] prior to LPS 
administration, 1,000 U/kg [454.5 U/lb] prior to LPS 
administration, and 5,000 U/kg after LPS administra-
tion), compared with control horses, with an earlier and 
more sustained decrease in TNF-α when polymyxin B 
was administered prior to LPS infusion.15 Significantly 
decreased TNF-α concentration was observed in the 
polymyxin B–treated foals of the study reported here in 
a similar pattern as the adult horse group that received 
polymyxin B after LPS infusion.15 Interestingly, differ-
ences in TNF-α concentration between the polymyxin 
B and control group were not observed until later time 
points (8 and 24 hours). The reason for this apparent 
delayed effect is uncertain, but timing of polymyxin B 
administration, dose of LPS, or faster recovery from 
LPS challenge may play a role. Likewise, TXB2, another 
marker of inflammation, is an inactive yet stable metab-
olite and surrogate maker of thromboxane A
2
. Throm-
boxane A2 is produced by activated platelets and has 
prothrombotic properties with increased production 
during inflammation such as occurs with septicemia 
or host exposure to LPS.15,16,18,41 In the present study, a 
significant decrease in plasma TXB
2
 concentration was 
observed in foals administered polymyxin B, compared 
with the control group. Collectively, this suggests that 
polymyxin B may attenuate some of the inflammatory 
mediator production associated with endotoxemia.
No difference in rectal temperature or heart rate 
was observed between groups in this study; conversely, 
authors of previous studies in adult horses have report-
ed significant improvement in heart rate and rectal tem-
perature in polymyxin B–treated horses, compared with 
control horses. However, this observation occurred 
only in horses that were administered polymyxin B 
prior to LPS administration.16,18 A previous study15 did 
conclude that the effectiveness of polymyxin B against 
LPS-induced alterations is dose and time (relative to 
LPS exposure) dependent. Polymyxin B was adminis-
tered after LPS infusion in the study reported here, as 
this  would be the most likely clinical scenario encoun-
tered in neonatal foals. However, one should consider 
that naturally occurring equine neonatal sepsis likely 
results in intermittent and repeated bouts of endotox-
emia rather than a solitary episode; thus, continued 
administration of polymyxin B (ie, every 8 hours) in 
clinical cases may attenuate clinical and biochemical 
alterations from endotoxemia as the temporal course of 
treatment progresses. Taken together, this information 
suggests that administration of polymyxin B should oc-
cur as soon as possible in clinical cases of suspected or 
confirmed neonatal septicemia. Furthermore, preemp-
tive polymyxin B administration to neonatal foals in the 
prodromal stages of septicemia or to those foals at high 
risk of developing septicemia, such as foals with failure 
of passive transfer of maternal antibodies or infected 
umbilical structures, may be beneficial.
Older reports suggest that 1 detrimental effect of 
IV polymyxin B administration is nephrotoxicosis, al-
though more recent studies13 have found that toxico-
sis is less common and severe than originally believed. 
Renal toxicosis associated with polymyxin B adminis-
tration is dose dependent, with the proposed mecha-
nism of increasing membrane permeability resulting in 
increased influx of cations, anions, and water, leading 
to cell swelling and lysis.13 Recent studies15,42 in adult 
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horses suggest that a dose of 6,000 U/kg, IV, every 8 
hours, maintains the ability to bind LPS yet remains 
devoid of nephrotoxic effects. Similarly, no evidence of 
overt nephrotoxicosis was detected in neonatal foals af-
ter IV administration of 3 doses of polymyxin B in the 
present study.
When the results of the present study are compared 
with those previously published, a crucial variable that 
must be considered is the various LPS doses used in 
different study protocols. In adult horses, the dose of 
LPS administered IV in experimental studies has varied 
from 20 to 250 ng/kg (9.1 to 113.6 ng/lb).15,16,18,28,43–45 
In the present study, an LPS dose of 0.5 µg/kg (500 ng/
kg) was administered over 30 minutes; this dose was 
selected on the basis of reports21–23 of experimental en-
dotoxemia in neonatal foals. Presumably, a lower LPS 
dose would result in less clinical, serum biochemical, 
and inflammatory alterations in foals, as observed in 
adult horse studies. Another limitation of this study 
was the inability to control the individual foal’s suscep-
tibility and response to LPS administration. The host 
response to a foreign pathogen is highly variable and 
may be partially governed by genetic variables.46 No-
table individual variation in the concentrations of in-
flammatory markers was observed in the present study, 
which influenced results of statistical analysis. Finally, 
the experimental method of inducing endotoxemia 
used in this study, although widely accepted, does not 
perfectly mimic the global effects of naturally occurring 
septicemia in neonatal foals. Thus, results from this 
study should be viewed in light of the limitations of the 
experimental method.
In the present study, administration of LPS to neonatal 
foals resulted in clinical signs of lethargy, anorexia, colic, 
and diarrhea as well as hypoglycemia, hyperlactatemia, 
neutropenia, and increased concentrations of inflammatory 
mediators. Administration of polymyxin B (6,000 U/kg, IV, 
q 8 h) improved some variables, but multicenter studies in-
vestigating the clinical efficacy of polymyxin B in foals are 
necessary.
a. SNAP Foal IgG Test, IDEXX Laboratories, Westbrook, Me.
b. Xylazine, Lloyd Inc, Shenandoah, Iowa.
c. 14-gauge, 3.5-inch IV catheter, Mila International, Erlanger, Ky.
d. Feeding and urethral catheter, Tyco Healthcare, Mansfield, Mass.
e. Endotoxin, Sigma-Aldrich, St Louis, Mo.
f. Polymyxin B, X-Gen Pharmaceuticals, Northport, NY.
g. Advia 120 Hematology System, Siemens, Tarrytown, NY.
h. Accutrend, Roche Diagnostics, Mannheim, Germany.
i. AlphaTRAK Blood Glucose Monitoring System Meter, Abbott 
Animal Health, North Chicago, Ill.
j. Vitros Chemistry System, Ortho-Clinical Diagnostics Inc, Raritan, NJ.
k. Strata-X SPE Tubes, Phenomenex, Torrance, Calif.
l. Equine TNF alpha ELISA kit, Thermo Scientific Inc, Rockford, Ill.
m. 2,3-dinor TXB2 ELISA kit, Caymen Chemical Co, Ann Arbor, Mich.
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From this month’s AJVR 
Effects of clopidogrel on the platelet activation response  
in horses
Marjory B. Brooks et al
Objective—To evaluate the platelet activation response before and after treatment with clopido-
grel in horses.
Animals—12 healthy adult mares.
Procedures—In a masked study, horses (6/group) were randomly allocated to alternately receive 
placebo or clopidogrel via nasogastric tube at a loading dose of 4 mg/kg followed by 2 mg/kg every 
24 hours. Blood samples were collected before and 72 hours after initiation of treatment for ADP- 
and collagen-induced light transmission aggregometry; determination of closure time in collagen-
ADP cartridges; modified thrombelastography for comparison of maximal amplitudes generated by 
kaolin, reptilase, and reptilase plus ADP activation; and flow cytometric tests to detect platelet 
fibrinogen binding, P-selectin expression, and phosphatidylserine externalization before and after ex 
vivo stimulation with thrombin, convulxin, thrombin with convulxin, and calcium ionophore.
Results—Clopidogrel administration induced a significant decrease in mean aggregation response to 
5µM and 10µM ADP stimulation; however, 2 horses had resistance to clopidogrel’s inhibitory action. Sig-
nificant differences after clopidogrel treatment were not found in any other tests of platelet function.
Conclusions and Clinical Relevance—Assays using commercially available reagents were 
configured to measure different variables of the platelet activation response; however, clopido-
grel’s platelet inhibitory action was only detected by ADP-induced light transmission aggregome-
try. Results also suggested that horses, like humans, have interindividual variability in response to 
clopidogrel that may influence the drug’s clinical efficacy as an antiplatelet agent. (Am J Vet Res 
2013;74:1212–1222)
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